Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
PD-1+VEGF bsAb | Bispecific antibody | Oncology/Cancer | Solid tumor | Phase I | Global (except China) |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
VE0-H52H3 | Human | Human VEGF110 Protein, His Tag (MALS verified) |
|
|
|
VE0-H5212 | Human | Human VEGF110 Protein, premium grade |
|
|
Human VEGFR1/R2 captured on Protein A Chip can bind Human VEGF110 Protein, His Tag (Cat. No. VE0-H52H3) with an affinity constant of 13.8 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Bevacizumab biosimilar (Qilu Pharma) | QL-1101 | Approved | Qilu Pharmaceutical Co Ltd | 安可达 | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Qilu Pharmaceutical Co Ltd | 2019-12-06 | Neoplasms; Colorectal Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Innovent Biologics) | IBI-305; IBI305; IBI 305; CHS-305 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达攸同, BYVASDA, Bevagen | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Innovent Biologics(Suzhou) Co Ltd | 2020-06-17 | Ovarian Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Pfizer) | PF-6439535; PF-06439535 | Approved | Pfizer Inc | Zirabev | EU | Carcinoma, Renal Cell; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Pfizer Europe Ma Eeig | 2019-02-14 | Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Elea) | Approved | Laboratorio Elea Phoenix Sa | Lumiere | Argentina | Macular Degeneration | Laboratorio Elea Phoenix Sa | 2018-04-26 | Macular Degeneration | Details | |
Bevacizumab biosimilar (Samsung Bioepis) | SP-8; SB-8 | Approved | Samsung Bioepis Co Ltd | Aybintio | EU | Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Renal Cell | Samsung Bioepis Nl Bv | 2020-08-19 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Ranibizumab biosimilar (Samsung Bioepis) | AM002; SB-11; SB11 | Approved | Samsung Bioepis Co Ltd | BYOOVIZ | EU | Macular Edema; Wet Macular Degeneration; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic macular oedema; Diabetic Retinopathy | Samsung Bioepis Nl Bv | 2021-08-18 | Macular Edema; Diabetic macular oedema; Wet Macular Degeneration; Macular Degeneration; Diabetic Retinopathy; Choroidal Neovascularization; Retinal Vein Occlusion | Details |
Bevacizumab biosimilar (Intas Pharmaceuticals) | INTP-24 | Approved | Intas Biopharmaceuticals | Bevatas | India | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Carcinoma, Renal Cell; Breast Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms | Intas Biopharmaceuticals | 2017-10-04 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Ranibizumab biosimilar (Formycon/Bioeq) | FYB-201 | Approved | Bioeq Gmbh | CIMERLI, Ranivisio | United States | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic Retinopathy | Coherus Biosciences Inc | 2022-08-02 | Macular Edema; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Macular Degeneration; Retinal Vein Occlusion; Choroidal Neovascularization; Diabetic Retinopathy | Details |
Bevacizumab biosimilar (AryoGen Biopharma) | BE1040V | Approved | Aryogen Biopharma | Stivant | Iran | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Uterine Cervical Neoplasms; Metastatic breast cancer; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Glioblastoma | Aryogen Biopharma | 2019-06-01 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Colorectal Neoplasms; Peritoneal Neoplasms; Metastatic breast cancer; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Zydus Cadila) | Approved | Zydus Cadila | Bryxta | India | Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Colorectal Neoplasms; Glioblastoma; Metastatic breast cancer; Carcinoma, Renal Cell | Zydus Cadila | 2017-01-01 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Metastatic breast cancer; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
Bevacizumab biosimilar (TOT Biopharm) | TAB-008; TOT-102; TAB008; TOT102 | Approved | 朴欣汀, Pusintin | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Tot Biopharm Co Ltd | 2021-12-01 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
Bevacizumab | G180CU; RO-4876646; RG-435; NSC-704865; G180CL; R-435; G180DL | Approved | Genentech Inc | 安维汀, Avastin | United States | Colorectal Neoplasms | Genentech Inc | 2004-02-26 | Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Recurrence; Infections; Respiratory Tract Infections; Pterygium; Leukemia; Arteriovenous Malformations; Ependymoma; Telangiectasia, Hereditary Hemorrhagic; HIV Infections; Leukemia, Myelogenous, Chronic; Kidney Neoplasms; Epistaxis; Head and Neck Neoplasms; Leiomyosarcoma; Fibrosarcoma; Telangiectasis; Meningeal Carcinomatosis; Rectal Neoplasms; Vaginal Neoplasms; Esophageal Neoplasms; Macular Edema; Anaplasia; Carcinoma, Renal Cell; Diabetes Mellitus, Type 2; Squamous Cell Carcinoma of Head and Neck; Abdominal Neoplasms; Granuloma, Lethal Midline; Hemangioblastoma; Carcinoma; Carcinoma, Basal Cell; Esthesioneuroblastoma, Olfactory; Carcinoid Tumor; Carcinoma, Ovarian Epithelial; Glioblastoma; Neurofibromatosis 2; Pancreatic Neoplasms; Neoplasms, Glandular and Epithelial; Virus Diseases; Papillomavirus Infections; Neoplasms, Squamous Cell; Respiratory Tract Diseases; Neoplasms; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Triple Negative Breast Neopl | Details |
Bevacizumab biosimilar(Dr. Reddy's Laboratories) | DRL-BZ | Approved | Dr.Reddy's Laboratories Ltd | Versavo, Persivia | India | Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Glioblastoma; Peritoneal Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell | Dr.Reddy's Laboratories Ltd | 2019-08-19 | Ovarian Neoplasms; Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Celltrion) | CTP-16; CT-16; CT-P16 | Approved | Celltrion Inc | Vegzelma | EU | Carcinoma, Renal Cell; Peritoneal Neoplasms; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Breast Neoplasms; Colorectal Neoplasms | Celltrion Healthcare Hungary Kft | 2022-08-17 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Aflibercept biosimilar (Momenta/Mylan) | M-710; MYL-1701P | Approved | Momenta, Mylan Nv | EU | Diabetes Complications; Myopia, Degenerative; Diabetic Retinopathy; Macular Edema; Retinal Vein Occlusion | Viatris Ltd | 2023-09-15 | Macular Edema; Myopia, Degenerative; Diabetic macular oedema; Diabetes Complications; Diabetic Retinopathy; Retinal Vein Occlusion | Details | |
Ranibizumab biosimilar (Intas Biopharmaceuticals) | Approved | Intas Biopharmaceuticals | Razumab | India | Macular Degeneration | Intas Biopharmaceuticals | 2015-01-01 | Macular Degeneration | Details | |
Ranibizumab biosimilar (Xbrane) | Approved | Xbrane Biopharma Ab | EU | Diabetic Retinopathy; Macular Edema; Wet Macular Degeneration; Diabetes Complications | Stada Arzneimittel Ag | 2022-11-09 | Macular Edema; Wet Macular Degeneration; Diabetes Complications; Macular Degeneration; Diabetic Retinopathy | Details | ||
Bevacizumab biosimilar (Boan Biopharma) | LY-01008 | Approved | 博优诺, Boyounuo | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Shandong Boan Biotechnology Co Ltd | 2021-05-07 | Carcinoma, Ovarian Epithelial; Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details | |
Bevacizumab biosimilar (Shanghai Henlius Biotech) | HLX-04; HLX04-O | Approved | Shanghai Henlius Biotech Inc | 汉贝泰 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Shanghai Henlius Biopharmaceuticals Co Ltd | 2021-11-30 | Solid tumours; Carcinoma; Rectal Neoplasms; Carcinoma, Ovarian Epithelial; Glioblastoma; Wet Macular Degeneration; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Macular Degeneration; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Bevacizumab biosimilar (Biocad) | BCD-021 | Approved | Biocad | Avegra | Russian Federation | Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Biocad | 2015-11-25 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Sinocelltech) | SCT-510; SCT510A; SCT-510A | Approved | SinoCelltech Ltd | 安贝珠 | Mainland China | Peritoneal Neoplasms; Uterine Cervical Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Glioblastoma; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | SinoCelltech Ltd | 2023-06-27 | Ovarian Neoplasms; Glioblastoma; Carcinoma, Ovarian Epithelial; Wet Macular Degeneration; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Ranibizumab biosimilar (Qilu Pharmaceutical) | BCD-300; QL-1205 | Approved | Biocnd, Qilu Pharmaceutical Co Ltd | Rimmyrah | EU | Myopia, Degenerative; Choroidal Neovascularization; Diabetes Complications; Macular Edema; Wet Macular Degeneration | Qilu Pharma Spain Sa | 2024-01-05 | Macular Edema; Myopia, Degenerative; Wet Macular Degeneration; Diabetic macular oedema; Diabetes Complications; Retinal Vein Occlusion; Macular Degeneration; Choroidal Neovascularization; Diabetic Retinopathy; Myopia | Details |
Bevacizumab biosimilar (Allergan/Amgen) | ABP-215 | Approved | Amgen Inc | Mvasi | United States | Glioblastoma; Carcinoma, Renal Cell; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Amgen Inc | 2017-09-14 | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Aflibercept biosimilar (Qilu Pharmaceutical) | QL-1207 | Approved | Qilu Pharmaceutical Co Ltd | Mainland China | Macular Degeneration; Diabetic macular oedema | Qilu Pharmaceutical Co Ltd | 2023-12-13 | Diabetic macular oedema; Macular Degeneration | Details | |
Ranibizumab biosimilar (Senju) | GBS-007; OT-701; SJP-0133 | Approved | Senju Pharmaceutical Co Ltd | Japan | Macular Degeneration | Senju Pharmaceutical Co Ltd | 2021-09-27 | Wet Macular Degeneration; Macular Degeneration | Details | |
Bevacizumab biosimilar (mAbixience) | MB02; BEVZ-92; BEVZ92-MB02; AP-01 | Approved | Mabxience Sa | Alymsys | Argentina | Colorectal Neoplasms; Carcinoma, Renal Cell; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms | Stada Arzneimittel Ag | 2013-10-25 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Neovasculgen | PI-VEGF165 | Approved | Human Stem Cells Institute | Neovasculgen | Russian Federation | Peripheral Arterial Disease | Human Stem Cells Institute | 2011-12-07 | Peripheral Arterial Disease; Peripheral Nerve Injuries | Details |
Bevacizumab biosimilar (CTTQ Pharma) | TQ-B2302 | Approved | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | 安倍斯 | Mainland China | Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | 2023-02-28 | Ovarian Neoplasms; Glioblastoma; Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar (Biocon/Mylan) | MYL-1402O | Approved | Biocon Ltd | Lextemy, KRABEVA, Abevmy | India | Carcinoma, Renal Cell; Colorectal Neoplasms; Ovarian Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Mylan Pharmaceuticals Private Ltd | 2017-11-27 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Brain Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Conbercept | FP-3; KH-902 | Approved | Chengdu Kanghong Biotechnologies Co Ltd | 朗沐, Langmu | Mainland China | Macular Degeneration | Chengdu Kanghong Biotechnologies Co Ltd | 2013-11-27 | Macular Edema; Vision Disorders; Wet Macular Degeneration; Diabetic macular oedema; Retinoblastoma; Hemangioma; Uveitis; Retinal Vein Occlusion; Choroidal Neovascularization; Corneal Neovascularization; Diabetes Mellitus; Macular Degeneration | Details |
Bevacizumab biosimilar(Apotex ) | Approved | Apotex Inc | BAMBEVI | Canada | Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Glioblastoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Apotex Inc | 2021-09-23 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Aflibercept | BAY-865321; BAT-86-5321 | Approved | Bayer AG | Eylea, 艾力雅 | United States | Macular Degeneration; Macular Edema | Regeneron Pharmaceuticals Inc | 2011-11-18 | Retinitis Pigmentosa; Choroidal Neovascularization; Carcinoma, Non-Small-Cell Lung; Corneal Neovascularization; Retinopathy of Prematurity; Neoplasm Metastasis; Diabetic Retinopathy; Retinal Vein Occlusion; Macular Degeneration; Vitreous Hemorrhage; Lymphoma, Non-Hodgkin; Retinal Degeneration; Eye Diseases; Diabetes Complications; Colorectal Neoplasms; Prostatic Neoplasms; Diabetes Mellitus, Type 1; Wet Macular Degeneration; Diabetic macular oedema; Multiple Myeloma; Myopia, Degenerative; Retinal Diseases; Colonic Neoplasms; Central Serous Chorioretinopathy; Neoplasms; Diabetes Mellitus, Type 2; Rectal Neoplasms; Choroid Diseases; Glaucoma, Neovascular; Macular Edema; Cataract | Details |
Bevacizumab biosimilar (Jiangsu Hengrui Medicine) | BP-102 | Approved | Jiangsu Hengrui Medicine Co Ltd | 艾瑞妥 | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2021-06-22 | Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ziv-aflibercept | BAY-865321; AVE-0005 | Approved | Sanofi | Zaltrap | United States | Colorectal Neoplasms | Sanofi-Aventis U.S. Llc | 2012-08-03 | Lymphoma; Breast Neoplasms; Urethral Neoplasms; Brain Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Carcinoma, Mucoepidermoid; Gliosarcoma; Astrocytoma; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Peritoneal Neoplasms; Ureteral Neoplasms; Lung Neoplasms; Prostatic Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Neuroendocrine; Glioma; Lymphoma, Non-Hodgkin; Thyroid Neoplasms; Carcinoma, Squamous Cell; Retinal Vein Occlusion; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Solid tumours; Leiomyosarcoma; Multiple Endocrine Neoplasia Type 1; Leukemia; Carcinoma; Carcinoma, Renal Cell; Carcinoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Leukemia, Myelomonocytic, Chronic; Ovarian Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Carcinoma, Transitional Cell; Carcinoma, Papillary; Small Cell Lung Carcinoma; Colonic Neoplasms; Ascites; Lung Diseases; Adenoc | Details |
Ranibizumab | RG-3645; rhu-Fab-VEG; AMD-rhuFab-V2; AMD-Fab; rhuFab-V2; RFB-002; Y-0317; RG-6321 | Approved | Novartis Pharma Ag, Genentech Inc | Lucentis, 诺适得, Susvimo | United States | Macular Degeneration | Genentech Inc | 2006-06-30 | Retinal Degeneration; Wet Macular Degeneration; Retinoblastoma; Vascular Diseases; Glaucoma; Retinal Detachment; Diabetes Complications; Pseudoxanthoma Elasticum; Retinal Neovascularization; Cardiovascular Diseases; Eye Diseases; Uveitis; Ischemia; Vitreous Hemorrhage; Hemangioma; Retinopathy of Prematurity; Diabetic Retinopathy; Choroidal Neovascularization; Retinal Vein Occlusion; Macular Degeneration; Melanoma; Conjunctival Neoplasms; Port-Wine Stain; Corneal Neovascularization; von Hippel-Lindau Disease; Myopia; Diabetes Mellitus; Telangiectasis; Cataract; Pterygium; Polypoidal choroidal vasculopathy; Diabetic Angiopathies; Retinal Telangiectasis; Vitreous Detachment; Epistaxis; Telangiectasia, Hereditary Hemorrhagic; Iris Diseases; Vision Disorders; Macular Edema; Glaucoma, Neovascular; Optic Neuropathy, Ischemic; Strongyloidiasis; Neovascularization, Pathologic; Depression; Central Serous Chorioretinopathy; Histoplasmosis; Retinal Diseases; Angioid Streaks; Myopia, Degenerative; Pathologic Processes; Mu | Details |
Bevacizumab biosimilar (Reliance Life Sciences) | R-TPR-023 | Approved | Reliance Life Sciences | BevaciRel | India | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Glioblastoma; Carcinoma, Renal Cell; Fallopian Tube Neoplasms; Carcinoma, Ovarian Epithelial; Peritoneal Neoplasms; Uterine Cervical Neoplasms | Reliance Life Sciences Pvt Ltd | 2016-06-13 | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Faricimab | RO-6867461; RG-7716 | Approved | F. Hoffmann-La Roche Ltd, Genentech Inc | Vabysmo, 罗视佳 | United States | Diabetic macular oedema; Wet Macular Degeneration | Genentech Inc | 2022-01-28 | Polypoidal choroidal vasculopathy; Macular Edema; Choroid Diseases; Vision Disorders; Retinal Diseases; Diabetic macular oedema; Wet Macular Degeneration; Diabetes Complications; Macular Degeneration; Diabetes Mellitus; Retinal Vein Occlusion; Diabetic Retinopathy; Choroidal Neovascularization | Details |
Bevacizumab biosimilar (Hetero Drugs) | Approved | Hetero Drugs Ltd | Cizumab | India | Colorectal Neoplasms | Hetero Drugs Ltd | 2016-06-27 | Colorectal Neoplasms | Details | |
Bevacizumab biosimilar (Bio-Thera Solutions) | BAT-1706 | Approved | Bio-Thera Solutions Ltd | 普贝希, AVZIVI | Mainland China | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms | Bio-Thera Solutions Ltd, Beigene Ltd | 2021-11-17 | Ovarian Neoplasms; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Glioblastoma; Neoplasms; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular | Details |
Bevacizumab biosimilar (Betta/Mabworks) | MIL-60 | Approved | Institute Of Basic Medicine, Chinese Academy Of Medical Sciences, Beijing Mabworks Biotech Co Ltd | 贝安汀 | Mainland China | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Betta Pharmaceuticals Co Ltd | 2021-11-24 | Carcinoma, Ovarian Epithelial; Glioblastoma; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Bevacizumab biosimilar(Jiangsu Aosaikang) | ASK-1202; AMD-B; AK-3008; ASK-B1202; ASKB1202 | Phase 3 Clinical | Jiangsu Aosaikang Pharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ranibizumab biosimilar (Reliance Life Sciences Group) | R-TPR-024 | Phase 3 Clinical | Reliance Life Sciences | Macular Degeneration | Details |
TR-009 | NOV-1501; ABL001-ABL Bio; ABL-001-ABL Bio; ES-104; CTX-009; HD-B001A; HDB001A; TR-009 | Phase 3 Clinical | Abl Bio Inc | Biliary Tract Neoplasms; Solid tumours; Rectal Neoplasms; Colonic Neoplasms; Neoplasms; Cholangiocarcinoma; Bile Duct Neoplasms; Colorectal Neoplasms; Gallbladder Neoplasms | Details |
Bevacizumab biosimilar (Fudan-Zhangjiang) | Phase 3 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Colorectal Neoplasms; Macular Degeneration; Carcinoma, Non-Small-Cell Lung | Details | |
Aflibercept Biosimilar (Alteogen) | ALT-L9 | Phase 3 Clinical | Alteogen Inc, Kissei Pharmaceutical Co Ltd | Macular Degeneration | Details |
Bevacizumab biosimilar (Huaota Biopharm/Shanghai Junshi Biosciences) | JS-501; HOT-1010 | Phase 3 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Prestige BioPharma/Hanwha Biologics) | HD-204 | Phase 3 Clinical | Hanwha Biologics | Small Cell Lung Carcinoma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Bevacizumab biosimilar (Oncobiologics) | ONS-5010; ONS-1045 | Phase 3 Clinical | Outlook Therapeutics Inc | Diabetic macular oedema; Wet Macular Degeneration; Retinal Vein Occlusion; Macular Degeneration | Details |
Aflibercept biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Macular Degeneration | Details | |
Bevacizumab biosimilar (Alphamab/R-Pharm) | RPH-001 | Phase 3 Clinical | Suzhou Alphamab Co Ltd, R-Pharm | Colorectal Neoplasms | Details |
Bevacizumab biosimilar(Zhejiang Teruisi Pharmaceutical) | TRS-003 | Phase 3 Clinical | Zhejiang Teruisi Pharmaceutical Inc | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Ranibizumab biosimilar (Chong Kun Dang Pharmaceutical) | CKD-701 | Phase 3 Clinical | Chong Kun Dang Pharmaceutical Corp | Macular Degeneration | Details |
Ranibizumab biosimilar (Lupin) | LUBT-010 | Phase 3 Clinical | Lupin Ltd | Macular Degeneration | Details |
Abicipar pegol | MP-0112; AGN-150998 | Phase 3 Clinical | Molecular Partners Ag | Macular Edema; Diabetic macular oedema; Macular Degeneration | Details |
Bevacizumab biosimilar (Genor Biopharma) | GB-222 | Phase 3 Clinical | Genor Biopharma Co Ltd | Brain Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Solid tumours; Liver Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Aflibercept biosimilar (Amgen) | ABP-938 | Phase 3 Clinical | Amgen Inc | Vascular Diseases; Macular Degeneration | Details |
Bevacizumab biosimilar (Centus Biotherapeutics) | FKB-238 | Phase 3 Clinical | Fujifilm Kyowa Kirin Biologics Co Ltd | Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Breast Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Bevacizumab biosimilar(Laboratorios Sophia) | PRO-169 | Phase 3 Clinical | Laboratorios Sophia Sa De Cv | Diabetic macular oedema | Details |
Aflibercept Biosimilar(Alvotech Swiss) | AVT-06 | Phase 3 Clinical | Alvotech Swiss Ag | Vascular Diseases; Macular Degeneration | Details |
Aflibercept biosimilar (HEXAL/Sandoz) | SOK-583A1; SOK583A1; SOK-583 | Phase 3 Clinical | Sandoz, Hexal | Macular Degeneration | Details |
CT-P42 | CT-P42 | Phase 3 Clinical | Celltrion Inc | Macular Edema; Diabetic macular oedema | Details |
Aflibercept biosimilar (Mabwell) | 9-MW-0813; 9MW-0813; 9MW0813; 9-MW0813 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Diabetic macular oedema | Details |
Bevacizumab biosimilar (Beijing Science Sun/Beijing Lvzhu) | K-11 | Phase 3 Clinical | Beijing Lvzhu Biological Technology Co Ltd, Beijing Science Sun Pharmaceutical Co Ltd | Liver Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular | Details |
FYB-203 | FYB-203 | Phase 3 Clinical | Macular Degeneration | Details | |
Aflibercept biosimilar (Sam Chun Dang Pharm) | SCD-411 | Phase 3 Clinical | Sam Chun Dang Pharm Co Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
Aflibercept biosimilar (Samsung Bioepis) | SB-15; AM003; SB15 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Solid tumours; Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
Aflibercept Biosimilar (Boan Biopharma/Luye Pharma) | LY-09004; BA-9101; OT-702 | Phase 3 Clinical | Luye Pharma Group Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
Varisacumab | R-84; GNR-011; AT-001-IBCG | Phase 3 Clinical | Peregrine, The University Of Texas Southwestern Medical Center | Glioblastoma; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MP-0250 | MP-0250 | Phase 2 Clinical | Molecular Partners Ag | Neoplasms; Multiple Myeloma; Carcinoma, Non-Small-Cell Lung | Details |
ALS-L1023 | ALS-L1023 | Phase 2 Clinical | Angiolab Inc | Sleep Bruxism; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Syndrome; Temporomandibular Joint Disorders; Macular Degeneration | Details |
Bevacizumab biosimilar (Eastern Biotech) | JY-028 | Phase 2 Clinical | Beijing Eastern Biotech Co Ltd | Wet Macular Degeneration; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration | Details |
Intravitreal ranibizumab (Sultan Qaboos University) | Phase 2 Clinical | Sultan Qaboos University | Retinal Dystrophies | Details | |
ELGN-EYE | ELGN-EYE | Phase 2 Clinical | Elgan Pharma Ltd | Retinopathy of Prematurity | Details |
SCT-501(National Cancer Institute) | SCT-501 | Phase 2 Clinical | National Cancer Institute | Kidney Neoplasms | Details |
Y-400 | Y-400 | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Wet Macular Degeneration; Diabetic macular oedema; Macular Degeneration | Details |
BI-836880 | BI-836880 | Phase 2 Clinical | Ablynx Nv | Neoplasms; Wet Macular Degeneration | Details |
SYB-509 | SYB-509 | Phase 1 Clinical | Sichuan Yuanda Shuyang Pharmaceutical Co Ltd | Carcinoma, Transitional Cell; Carcinoma, Hepatocellular | Details |
Vanucizumab | RG-7221; RO-5520985; B800Z06O8K (UNII code) | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms; Colorectal Neoplasms | Details |
Bevacizumab biosimilar (North China Pharmaceutical) | MG-021 | Phase 1 Clinical | North China Pharmaceutical Company Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Macular Degeneration | Details |
Bevacizumab biosimilar(Guilin Sanjin) | Phase 1 Clinical | Guilin Sanjin Pharmaceutical Co Ltd | Macular Degeneration | Details | |
Ranibizumab biosimilar (CJSC Generium) | GNR-067 | Phase 1 Clinical | Cjsc Generium | Macular Degeneration | Details |
Bevacizumab biosimilar (Shanghai Kangdai) | Phase 1 Clinical | Shanghai Kanda Bio-Technology Co Ltd | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details | |
Bevacizumab biosimilar (JHL Biotech) | JHL-1149 | Phase 1 Clinical | JHL Biotech | Neoplasms | Details |
Ziv-aflibercept biosimiliar (Boan Biopharma) | LY-01012; BA-1103 | Phase 1 Clinical | Colorectal Neoplasms | Details | |
Bevacizumab biosimilar (Tanvex BioPharma) | TX-16 | Phase 1 Clinical | Tanvex Biopharma | Colorectal Neoplasms | Details |
PB-101 | PB-101 | Phase 1 Clinical | Panolos Bioscience Inc | Solid tumours; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Carcinoma, Hepatocellular | Details |
IBI-333 | IBI-333 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Wet Macular Degeneration; Macular Degeneration | Details |
IBI-324 | IBI-324 | Phase 1 Clinical | Innovent Biologics (Usa), Inc | Diabetic macular oedema | Details |
Y-332 | Y-332 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd, Wuhan Yzy Medical Science And Technology Co Ltd | Solid tumours | Details |
Dilpacimab | ABT-165; DVD-Ig ABT-165 | Phase 1 Clinical | Abbvie Inc | Solid tumours; Neoplasms | Details |
Bevacizumab biosimilar (Gedeon Richter) | Phase 1 Clinical | Gedeon Richter Plc | Neoplasms | Details | |
HG-202 | HG-202; HG202 | Phase 1 Clinical | HuiGene Therapeutics Ltd | Wet Macular Degeneration; Macular Degeneration | Details |
Aflibercept biosimilar (Zein Bioteccnology) | Phase 1 Clinical | Zein Bioteccnology Co Ltd | Diabetic macular oedema | Details | |
VEGFA-targeting Gene Therapy(BDgene) | BD311 | Phase 1 Clinical | Shanghai BDgene Technology Co Ltd | Diabetic macular oedema; Macular Degeneration; Retinal Vein Occlusion | Details |
ASKG-712 | ASKG-712; AM-712 | Phase 1 Clinical | Askgene Pharma | Diabetic macular oedema; Wet Macular Degeneration; Macular Degeneration | Details |
OB-318 | OB-318 | Phase 1 Clinical | Oneness Biotech Co Ltd | Solid tumours; Carcinoma, Hepatocellular | Details |
Bevacizumab biosimilar(Guangdong Dongyangguang) | Phase 1 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung | Details | |
Colorectal cancer vaccine (Immunovo/Pepscan Therapeutics) | Phase 1 Clinical | Pepscan Systems | Colorectal Neoplasms | Details | |
Bevacizumab biosimilar(Bioxpress) | BXT-2316 | Clinical | Bioxpress Therapeutics Sa | Carcinoma, Renal Cell; Glioblastoma; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
This web search service is supported by Google Inc.